Peripheral Blood CD34+ Stem/Progenitor Cells, Frozen

Human peripheral blood CD34+ stem and progenitor cells are positively selected using immunomagnetic anti-CD34 (clone QBEND10) microbeads from the mononuclear cell fraction. Isolated primary cells are characterized by flow cytometry before cryopreservation to ensure a highly pure and viable cell population.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.

Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies.  By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

CGT Global - Landing Page Desktop Prototype

Description

CD34 is a glycosylated transmembrane protein and represents a well-established marker for human hematopoietic stem and progenitor cells in peripheral blood, bone marrow, and cord blood. CD34+ cells are self-renewing, multipotent stem cells that give rise to all blood cells of the immune system through a process called hematopoiesis. As hematopoietic stem cells progress through hematopoiesis they generate the myeloid (monocytes, macrophages, granulocytes, megakaryocytes, dendritic cells, erythrocytes) and lymphoid (T cells, B cells, NK cells) lineages. The highly specialized cells that arise from hematopoietic stem cells work collaboratively in defending the body against infection and disease.

 

Additional information

Anticoagulant

Format

Grade

Species

Cell and Tissue Source

Disease State

Donor Attributes

Product Information Sheet

 

 

Figure 1. Representative flow data of enriched CD34+ cells from peripheral blood prior to cryopreservation.